Gaush Meditech Ltd
高视医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT
FEMTOSECOND LASER AND ITS SUPPORTING CONSUMABLES OBTAINED NMPA MEDICAL DEVICE REGISTRATION CERTIFICATE

This announcement is made by Gaush Meditech Ltd (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that, Femtosecond Laser (scope of application: creation of corneal flap in femtosecond laser-assisted in situ keratomileusis (Femto-LASIK)) and its supporting Patient Interface for SCHWIND ATOS launched by SCHWIND eye-tech-solutions GmbH, an important upstream partner represented by Mingwang Medical Ltd.* (上海高視明望醫療器械有限公司), a wholly-owned subsidiary of the Company, recently obtained the medical device registration certificate approved by the National Medical Products Administration (NMPA) of the People's Republic of China.

Such system mainly features: (i) the use of CenTrax® intelligent center positioning and eye-tracking technology to provide greater safety and predictability; (ii) the use of ultra-high laser frequencies, with laser scanning frequencies up to 4MHz, making surgery more efficient and more comfortable for patients; (iii) an optimized arc-shaped integrated negative pressure ring, which has an optimized arc-shaped interface that conforms to the corneal curvature and will not cause deformation of the eyeball and cornea, providing greater patient comfort; and (iv) a personalized ultra-thin corneal flap that provides more surgical space for personalized surgery. The maximum flap diameter can reach 9.6 mm, providing sufficient treatment light zone, especially suitable for the treatment of hyperopia and mixed astigmatism.

The approval of such surgery system and its supporting consumables have further enriched the Group's product portfolio, especially high-end surgical treatment products. The Group will continue to bring more and better products and solutions to its customers and patients.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, March 12, 2025

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

** For identification purposes only*